SAMANTHA DILL: Open Payments
NPI 1124681465 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$758 in 44 payments from 14 companies in 2025. Trend: 2023 $1,105 · 2024 $1,253 · 2025 $758
Food & beverage: $758
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 8 | $134 |
| Otsuka America Pharmaceutical, Inc. | 6 | $128 |
| ABBVIE INC. | 6 | $106 |
| Eisai Inc. | 5 | $82 |
| Novo Nordisk Inc | 5 | $78 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| PFIZER INC. | 2 | $29 |
| Amgen Inc. | 2 | $28 |
| Edwards Lifesciences Corporation | 1 | $27 |
Products named: REXULTI, UBRELVY, AMYVID, Leqembi, Ozempic, XIFAXAN, MOUNJARO, SAPIEN 3 Ultra RESILIA.
Industry payments across AR — which companies pay providers there.
